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p120-catenin was first described in 1989 as a Src substrate whose phosphorylation correlated with transformation. It was identified by cDNA
cloning in 1992, and shown to interact with cadherins in 1994. Though enigmatic for some time, p120 has emerged as a master regulator of
cadherin stability, and an important modulator of RhoGTPase activities. With the discovery of p120 family members and evidence for fundamental
roles in cell biology and cancer, the field has expanded dramatically in recent years. As an introduction to this collection of reviews on p120 and
its relatives, the editors have requested a personal commentary and historical perspective on the discovery of p120. The anecdotal parts have no
particular purpose, but are mostly unpublished and perhaps of interest to some.
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p120-catenin (hereafter p120) was first reported in 1989 as a
Src substrate whose phosphorylation correlated with transfor-
mation [1]. It was identified by cDNA cloning in 1992 [2], and
shown to interact with cadherins in 1994 [3,4]. Though
enigmatic for some time, p120 has emerged as a master regulator
of cadherin stability [5–7], and an important modulator of
RhoGTPase activities [8–10]. Reports of functional interactions
with other Src substrates (e.g., Cortactin), and transcription
factors (e.g., Kaiso) [11–15] indicate that like β-catenin, p120 is
likely to have multiple roles in different cellular compartments.
Indeed, p120 is physically or functionally linked to a wide
variety of oncogenes and tumor suppressors, including Src
kinases, receptor tyrosine kinases, receptor tyrosine phospha-
tases, E-cadherin, β-catenin, APC, RhoGTPases, Kaiso, and
Wnt signaling effectors. These observations suggest prominent
roles in cellular activities associated with cancer, including cell
adhesion, motility, morphology, and growth. Interestingly, the
extended p120 family might have in common the ability regulate
RhoGTPases, but their individual roles are not necessarily
limited to regulation of cell–cell adhesion. The focus of this⁎ Tel.: +1 615 343 9532.
E-mail address: al.reynolds@vanderbilt.edu.
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.09.019BBA volume on p120 and it family members is indicative of
the growing interest in these proteins, and suggests a bright
future for the field as it endeavors to unravel underlying
mechanisms and potential roles in disease and cancer. As re-
quested by the editors of this volume, this introductory chapter is
intended not as a review, but rather a personal commentary
and historical perspective on the discovery of p120 and potential
future directions.
2. An historical Perspective
p120 was initially identified as part of a larger effort to
determine the mechanism of cell transformation by v-Src [1]. At
the time, it was one of many Src-substrates whose visualization
was made possible for the first time by a technical advance,
namely the advent of antibodies to phosphotyrosine (pTyr anti-
bodies). There was substantial concern that p120 and the other
substrates observed by this method might turn out to be irrelevant
cytoskeletal proteins phosphorylated promiscuously because of
their abundance, or due to an overexpressed kinase gone bad. On
the other hand, p120 was unique among the substrates in that it
was not phosphorylated by a transformation-defective Src
variant, suggesting a possible role in oncogenic cell transforma-
tion. In any event, the substrates were purified en masse by pTyr-
antibody affinity chromatography and monoclonal antibodies
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strates were then pooled, and used to screen cDNA expression
libraries. Remarkably, the majority of the major substrates,
known only as pTyr bands on a Western blot in 1989, were both
identified and cloned by 1992 [2,17–19].
As with many scientific endeavors, luck played an important
role. For example, during generation of the substrate mono-
clonal antibodies, the lone p120-specific positive clone was
very nearly lost. In a significant effort to rescue the unstable
hybridoma, a single subclone out of over 200 screened
remained positive, resulting in mAb 2B12—without which it
would have been difficult or impossible to pursue p120.
Persistence was also essential, however, as p120 was the only
protein in the substrate collection whose cDNA could not be
isolated by antibody-based expression cloning. Expression
libraries at that time were generated by reverse transcribing
mRNA using 3′ poly-A tails as cDNA primer templates. Thus,
the 5′ ends of cDNA coding sequences were often under-
represented or absent. According to classic Murphy doctrine,
mAb 2B12 recognized an epitope at the extreme 5′ end of the
longest cDNA coding sequence. This chance occurrence also
delayed the recognition of p120's multiple personalities.
Antibodies to other p120 regions recognize all p120 isoforms,
but mAb 2B12 interacted with an epitope found only in p120
isoform 1. Nonetheless, the antibody provided a specific handle
for p120 purification, and the gene was eventually cloned by
more labor-intensive methods [2] (i.e., large scale immunopre-
cipitation, extraction from SDS-polyacrylamide gels, digestion
with cyanogen bromide, peptide microsequencing by Edman
degradation, PCR from redundant oligonucleotides to generate
exactly matched cDNA probes, and conventional screening of
λgt10 libraries), that thankfully, have been made mostly
irrelevant by the human genome project.
Interestingly, p120 and most of the other genes isolated in
these screens (i.e., Tensin, Focal Adhesion Kinase/FAK,
p130CAS, p110AFAP, cortactin) turned out to be novel, and
did indeed encode bona fide physiologically relevant Src
substrates. With the exception of p120, each contained domains
that were obviously relevant to protein tyrosine kinase (PTK)
signaling (e.g., PTK, SH2, or SH3 domains). p120, on the other
hand, contained linked armadillo repeats with only 22% identity
to β-catenin or plakoglobin. Nonetheless, an “Armadillo repeat”
consensus pattern could be identified, suggesting for the first
time that proteins other than β-catenin and plakoglobin might
utilize this motif for a generalized purpose. The observation led
to the recognition that linked Arm repeats form a functional
domain (dubbed the Arm domain)[20] that has since been
identified in numerous proteins. Importantly, the structural
relationship to β-catenin also led to the idea that p120 might
physically associate with cadherins [3]. In retrospect, however,
the finding itself was at least partly a matter of luck—despite the
impeccable logic behind the experiment, the vast majority of
Arm domain proteins discovered subsequently (p120 family
members excepted) do not interact with cadherins.
Although it is difficult to assign a single role to Src, an
important lesson from the Src substrate project was the general
recognition that Src-substrates have in common the ability toregulate the actin cytoskeleton. Thus, despite the number and
complexity of its substrates, an overarching role of c-Src may be
to coordinate actin-dependent cellular activities, such as
adhesion and motility. Although p120 did not initially seem to
conform to the Src pattern (i.e., lack of typical PTK-associated
domains), both β-catenin and plakoglobin are excellent Src
substrates, and are in fact well-established mediators of a
functional connection to the underlying actin cytoskeleton. In
retrospect, these observations provided the first clue that p120
would also participate in regulating actin dynamics. Indeed, it
has become increasingly valuable to think about p120 in the
context of a functional network of Src substrates (e.g., FAK,
cortactin) that coordinate actin-based events underlying cell
morphology, motility, and adhesion.
The interaction between p120 and E-cadherin was formally
reported in 1994 [3] and at the ASCB meeting of that year,
where a prominent scientist remarked that p120 did indeed
look like an interesting protein, but that it should have been
given a better name (e.g., integrins). At the summer Oncogene
meetings, p120 had in fact been officially dubbed CAS
(Cadherin-Associated Src Substrate), an unimaginative but
appropriate moniker that described virtually everything known
about p120 at the time. Incredibly, another Src substrate, p130,
was also cloned that year, and the authors chose to name the
protein CAS (Crk-Associated Substrate)[21]. The two posters
appeared side by side at the Oncogene meeting, leading to
considerable confusion. Thus, it was eventually resolved that
p120CAS would become p120ctn (for catenin). For better or
worse, the moniker is now irrevocably engrained in the
literature.
The field was slow to bring p120 into its models of the
cadherin complex. Interestingly, our seminal manuscript
reporting the p120-cadherin interaction was editorially rejected
(lack of functional significance) by the Journal of Cell Biology
and had to be resubmitted elsewhere [3]. p120-cadherin
coimmunoprecipitation experiments were difficult to repeat
because the interaction is of relatively low affinity in detergent
lysates. Moreover, in a particularly powerful demonstration of
Murphy's law, the main p120 isoforms comigrated exactly with
α- and β-catenins in many cell types [3]. Methods used
frequently at that time to detect α- and β-catenins in cadherin
immunoprecipitates (e.g., 35S-methionine labeling and auto-
radiography) were virtually useless because p120 bands were
masked by α- and β- catenins. Thus, it was necessary to prove
that the coprecipitating bands recognized by p120 mAbs on
Western blots were not cross reacting with the exactly
comigrating α- and β-catenins. Nonetheless, p120 colocalized
precisely with cadherins in most cell types, and localized
aberrantly to the cytoplasm in metastatic cell lines that had lost
E-cadherin. Eventually, direct mapping experiments, and the
uncoupling of p120 binding by minimal mutations in the
cadherin juxtamembrane domain offered indisputable proof
[22,23]. Cadherins are in fact both necessary and sufficient for
recruitment of p120 to membranes/junctions [22]. It is as yet
unclear whether the apparent low affinity of the interaction is
functionally important in cells, as suggested by mechanistic
models where cytoplasmic p120 and/or shuttling between a
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(e.g., see review by Anastasiadis in this volume).
The discovery of Kaiso in 1999 as a novel p120 binding
partner provided the first tangible evidence that p120might have
additional roles in the nucleus [11]. The possibility was implied
by analogy to β-catenin, and later supported by localization
studies in cadherin-deficient cells [25]. It is now clear that these
proteins interact functionally at the level of transcription [15,26].
Moreover, recent studies in Xenopus have revealed novel
interactions with Wnt signaling pathways [13,14] (see the
reviews by Daniel, and by McCrea and Park in this volume).
Interestingly, in the context of APC(Min/+) mice, Kaiso-
deficiency results in a partial resistance to intestinal cancer
[27]. An interesting possibility is that p120 and β-catenin may
collaborate functionally to control cell–cell adhesion at the level
of cadherin complex, and then again in the nucleus as their
signaling pathways converge on Wnt effectors.
Functional interactions between p120 and RhoGTPases were
reported in 2000 [8–10], providing the first convincing evidence
that p120 might play a major role in controlling the interplay
between cadherins and the underlying actin cytoskeleton. The
mechanism(s) are now front and center in the field, in part
because it is clear that RhoGTPases control cadherin function,
and vice versa [28]. It has been known for some time that p120
overexpression in fibroblasts induces a striking branching
morphology [29]. The series of papers in 2000 connected this
phenotype to the suppression of Rho, and to some extent
activation of Rac. Such activities are likely shared by most or all
members of the p120 family, because most, including at least
some of the more distantly related plakophillins, can induce
branching phenotypes when overexpressed. Because p120 can
interact directly with Rho in vivo [30], and can keep Rho in an
inactive GDP-bound form in vitro [8], it was suggested that it
might act by sequestering Rho in its inactive state—as described
previously for Guanine Nucleotide Dissociation Inhibitors
(GDIs). Co-overexpression of a cadherin cytoplasmic domain
reverses the p120-induced branching phenotype, implying that
interaction of p120 with cadherins and Rho might be mutually
exclusive [8]. These observations suggest a RhoGDI-like model,
and a role for p120 in suppression of Rho in the cytoplasm, but
are based almost entirely on overexpression studies and are thus
subject to interpretation. While roles for p120 in controlling
RhoGTPases have been confirmed in many studies, including in
vivowork in developmental systems [30–32], the current models
do not adequately account for the central role played by
RhoGTPases in membrane associated cadherin complexes. Our
unpublished data implies that p120 can target suppression of
Rho to cadherin complexes via transient recruitment of
p190RhoGAP (Wildenberg/Reynolds, submitted). Other obser-
vations suggest that p120 might be essential for cadherin-
mediated activation of Rac [33]. These ideas are not mutually
exclusive, and may reflect a diversity of binding partners and
functions (e.g., β-catenin) as well as cell type specific
mechanisms. Indeed, differences in how Rac and Rho are used
from one cell type to another are well established and represent a
major complication for the RhoGTPase field, and now the p120
field as well.A key advance in 2002 was the discovery that p120 is
essentially a master regulator of cadherin stability [5–7]. This is
likely its core function at the level of the cadherin complex—in
the absence of p120, most cadherins are internalized and often
degraded, suggesting that p120 controls cadherin turnover at the
cell surface. The mechanism is post-translational and requires
direct physical interaction between p120 and the cadherin
complex [5]. It has been known for some time that the stability
of α-catenin and β-catenin is directly dependent on physical
interaction with cadherins [34]. The amount of cadherin present
is therefore rate limiting at the protein–protein interaction level
for stabilizing α- and β-catenins. In contrast, cadherin stability
is directly dependent on p120. Thus, in the hierarchy of who
controls what, p120 is at the top of the pyramid, and in fact, the
entire cadherin complex is degraded if p120 is selectively
removed (e.g., by RNAi methods, etc).
The implications of this novel arrangement are deceptive,
and have yet to be fully appreciated. For example, it strongly
implies that cadherins compete for an essentially limiting pool
of p120, and are removed from the cell surface if p120 is
unavailable. Thus, overexpression of any classical cadherin
cytoplasmic domain (i.e., DN-cadherin constructs) sequesters
the apparently limiting amounts of p120 such that the
endogenous cadherins are internalized and either degraded or
recycled, along with their dependant partners, α- and β-catenin.
An extensive preexisting literature based on in vitro and in vivo
use of dominant negative (DN) cadherins provides multiple
examples of this phenomenon, but does not attribute the
adhesive defects to loss of p120 function. Though other events
could contribute, it is now clear that the p120-based mechanism
described above is central. Thus, it might be constructive to
reexamine prior in vitro and in vivo DN-cadherin studies in the
context that they in fact reflect consequences of physically
removing p120. Of particular interest are in vivo transgenic
studies in the intestine and the pancreas, where DN-cadherin
expression induced adenomas, and dramatically increased
metastasis, respectively [35,36]. Studies using direct p120-
ablation in mice are underway to determine whether p120-loss
by itself will indeed recapitulated these observations.
Interestingly, the above phenomenon is also relevant when
one overexpresses full-length classical or type II cadherins (e.g.,
N-cadherin) in cells that already express other p120-dependant
cadherins (e.g., E-cadherin). The predicted (and actual) con-
sequence based on the above data is not simply co-expression
of N-cadherin with E-cadherin. Instead, the ectopic N-cadherin
sequesters the available p120, and endogenous E-cadherin is
efficiently internalized. The end result is essentially the
replacement of one cadherin by another via a largely post-
transcriptional mechanism. In cells that naturally express more
than one cadherin, it is evident that they somehow share and/or
compete for a limiting amount p120. Conversely, if a particular
cadherin is artificially eliminated (e.g., by knockout or knock-
down), levels of the remaining cadherin(s) often increase. For
example, targeted knockout of E-cadherin in the mouse
epidermis increases P-cadherin levels [37]. How cells monitor
and regulate p120 levels to accommodate these needs is
currently unknown, but it is clear that p120 expression levels
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overall cadherin levels. These observations highlight the
importance of better understanding the status of p120 in
human tumors: there are numerous reports of p120 down-
regulation in cancer, but the cause(s) are unknown and the
relative importance of the phenomenon in tumor progression has
not been determined [38].
This year (2006) marks the culmination of a great deal of
effort aimed at directly addressing some of these issues in vivo
by examining controlled p120 ablation in mice. Conventional
p120 KO in mice is embryonic lethal but two conditional p120
KO mouse models have now been generated and three
manuscripts detail for the first time the consequences of
targeted p120 KO in mammalian tissues [39–41]. As predicted
from in vitro studies, endogenous cadherins (e.g., E-, N-, and
P-cadherins) are significantly downregulated in all cell systems
targeted to date, including neurons and the epithelial linings of
the gut, prostate, epidermis, and salivary gland. In many cases,
cell–cell adhesion and cell morphology is significantly
impaired, but the severity of p120 KO with respect to cell
adhesion and morphology differs markedly from one system to
the next. A likely explanation is the variable presence of p120
family members with at least partially redundant functions. To
accelerate progress, the conditional p120 KO animals have been
widely distributed to interested laboratories with the goal of
more rapidly examining and comparing consequences of p120-
loss in diverse organ systems.
An unanticipated consequence of p120 loss in multiple organ
systems is inflammation. In the intestines and colon, severe
defects in cell–cell adhesion contributed to obvious breakdown
of the epithelial barrier function and exposure to bacteria and
other gut contents (A. Reynolds, unpublished). In the epidermis,
however, cell–cell adhesion was not obviously compromised,
and the barrier function appeared intact. Here, inflammation was
attributed to constitutive cell autonomous activation of RhoA
and downstream NFkB activity [40]. p120-ablation by siRNA
treatment does, in fact, dramatically increase Rho activity in a
wide variety of cell lines. Interestingly, severe inflammation
(i.e., neutrophil infiltration) was observed in the developing
salivary glands by embryonic day 16.5, despite the sterile
environment (M. Davis, unpublished). Thus, inflammation in
some cases may be the result of cell autonomous activation of
Rho/NFkB signaling and could be an important general
consequence of p120 downregulation. These observations
highlight the importance of targeting and comparing multiple
systems and reveal the potential of these mouse models for
advancing the study of p120 in development and disease. While
the long-term effects of p120-loss in vivo are not yet clear, the
early data – Rho activation, cadherin deficiency, defects in cell–
cell adhesion and morphology, and inflammation – are obvious
hallmarks of human cancer, and further highlight the need to
better understand p120-deficiency in human cancers.
The great historical irony with respect to p120 is that the role
of tyrosine phosphorylation remains unknown (see review by
Alema and Salvatore in this volume). The first publication on
p120 featured a strong correlation between p120 phosphoryla-
tion and transformation by Src. A role for p120 in transforma-tion has not been ruled out, but p120 knockdown does not
obviously block cell-transformation by Src. On the other hand,
p120 is required in MDCK cells for Src-induced growth in soft
agar (A. Reynolds, unpublished), and much of what we know to
date about p120 is indeed consistent with a role in transforma-
tion, including its association with cadherins, its role in
regulating RhoGTPases, and its functional link to p190Rho-
GAP. Advances in other aspects of p120 biology may provide
important clues for reexamining these issues. For example, the
observation that p120 is essential for stabilizing and retaining
cadherins at the cell surface is a critical finding and provides a
solid basis for modeling positive and negative p120 effects at
the mechanistic level. p120 binding partners described in recent
years include the kinases Fer, Yes, and Fyn, as well as several
tyrosine phosphatases (DEP-1, PTPu, SHP-2, etc.) (reviewed in
[42], which can now be incorporated into these models.
Moreover, most of the tyrosine and serine/threonine phospho-
rylation sites have been mapped and mutated [43,44], and there
are now elegant p120 knockdown and addback systems to
facilitate structure/function analyses [6]. Phosphospecific p120
antibodies have also been generated to many of the sites and
made widely available [45,46]. These reagents provide
necessary and powerful tools that will vastly accelerate studies
going forward. Though elusive, there is little doubt that p120
phosphorylation will play a critical role in regulating p120 and
cadherin function.
3. Back to the future
Publication rates on p120 and its family members have
accelerated from 5 in 2000 to over 55 in 2005. The practically
exponential increase in interest will ensure rapid progress over
the next decade. The field has reached a critical mass in terms of
the number of labs involved and the generation of a wide variety
of outstanding reagents. While many interesting questions
remain, it is worth mentioning here a few issues of particular
relevance in the near future.
More emphasis on other p120 family members is essential.
Although p120 is ubiquitous, and likely the most abundant in
mammals, there is growing evidence that some p120 family
members are more widely expressed than previously thought.
Moreover, it appears that this family may have in common the
ability to regulate Rho. Although δ-catenin and ARVCF can
functionally substitute for p120 with respect to binding and
stabilization of E-cadherin [5], it is likely that the core function
inherited and retained by all of these proteins is the ability to
somehow regulate and coordinate RhoGTPases. It is possible
that the cadherin stabilizing function of p120 and the ability to
regulate Rho is one and the same, but evidence to date is
inconclusive. As demonstrated recently for p0071 (Hatzfeld,
personal communication, NCB/In Press), these proteins have
probably found creative uses for this potentially powerful
activity (i.e., binding/coordinating Rho), and it will be
important to independently assess the roles of each family
member. As part of this effort, it is now critical to develop better
mAbs to each family member and make them widely available,
as the paucity and availability of such reagents has limited
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has been very difficult to determine the extent to which the
consequences of p120-loss might be masked in some tissues by
redundant roles of family members because immunohistochem-
istry-competent antibodies are scarce or unavailable.
The role of p120 itself in modulating RhoGTPase activities
needs to be resolved at the mechanistic level, as it is likely to
account for the fact that cadherins are central regulators of
RhoGTPases and vice versa. Although p120 can clearly act in
GDI-like fashion to directly inhibit Rho, the location and
significance of this activity under conditions where p120 is not
overexpressed is not yet understood. New evidence suggests
that p120 may also inhibit Rho via recruitment of p190RhoGAP
to cadherin complexes (Wildenberg/Reynolds, submitted), and
other observations suggest a role for p120 in activation of Rac
[33]. Also, p0071 interacts directly with the RhoGEF, Ect2
(Hatzfeld, NCB: In Press), providing an example of Rho
activation by a p120 family member. Differences between how
various cell types use Rac and Rho may account for much of the
confusion, but different cell types also express different cad-
herins, which in turn are coupled to different receptor tyrosine
kinases. A potential solution to this underlying complexity is
to focus on a few representative cell lines/types that are already
well characterized in the literature with respect to oncogenic
signaling and roles for Rac and Rho. As the individual char-
acteristics of defined systems emerge, they can then be more
accurately compared and contrasted.
Understanding the role(s) of p120 phosphorylation, both
tyrosine and serine/threonine, will be essential for deciphering
mechanisms underlying the regulation of cadherin-based cell–
cell adhesion and how they relate to other cellular functions
(e.g., cell growth, contact inhibition, endothelial permeability).
A great deal of effort has been invested in developing the in
vitro and in vivo tools necessary for more efficient exploration
of these events. Cadherins in all tissues are physically and
functionally coupled to receptor tyrosine kinases (RTK's), and
p120 in particular with its relationship to RhoGTPases may play
central roles in modulating these interactions. One possibility is
that receptor signaling controls dynamic cell–cell adhesion by
modification of p120, which in turn regulates rapid addition or
removal of cadherins from the cell surface. As implied above,
these relationships are probably highly interdependent and
broadly relevant to multiple areas of cell biology, development
and cancer.
Although great progress has been made with respect to p120
function in the nucleus (e.g., Kaiso), the overall and relative
significance of such activities are as yet unclear. The critical
relationships to Wnt signaling observed in Xenopus should be
reexamined in mammalian models. Interestingly, several novel
nuclear p120-binding partners have been described recently at
conferences and will undoubtedly lead to exciting new areas of
research. Given the critical role(s) of β-catenin in the nucleus
and the overall importance of cadherins in cancer, the potential
for p120 and its relatives in the nucleus remains an important
frontier.
Finally, the emerging data justify more emphasis on
discriminating studies aimed at clarifying the role(s) of p120in human cancer. The pathology data are consistent with p120
downregulation in many human cancers [38], but these
observations represent snapshots in time and do not address
cause and effect. Direct analysis of targeted p120 ablation in
mice will reveal whether p120-ablation has the potential (by
itself or in combination with other oncogenic events) to promote
cancer, but cannot definitively determine whether p120 down-
regulation or mutation does in fact contribute to initiation or
progression of particular human cancers. Given that much of the
evidence summarized above is consistent with such a role, it
may be time to place more emphasis on determining whether the
pathology data reflects genuine alterations in genetic or
epigenetic events and whether they are relevant in some cancers
to human tumor progression. Perhaps over the next decade,
p120 and its family members will emerge as important players
in a variety of human diseases.
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